Sign up to Receive ATOTW Weekly – Email [email protected]
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Management of Poisoning
MOH CLINICAL PRACTICE GUIDELINES December/2011 Management of Poisoning Health Ministry of Sciences Chapter of Emergency College of College of Family Manpower Authority Physicians Physicians, Physicians Academy of Medicine, Singapore Singapore Singapore Singapore Medical Pharmaceutical Society Society for Emergency Toxicology Singapore Paediatric Association of Singapore Medicine in Singapore Society (Singapore) Society Executive summary of recommendations Details of recommendations can be found in the main text at the pages indicated. Principles of management of acute poisoning – resuscitating the poisoned patient GPP In a critically poisoned patient, measures beyond standard resuscitative protocol like those listed above need to be implemented and a specialist experienced in poisoning management should be consulted (pg 55). GPP D Prolonged resuscitation should be attempted in drug-induced cardiac arrest (pg 55). Grade D, Level 3 1 C Titrated doses of naloxone, together with bag-valve-mask ventilation, should be administered for suspected opioid-induced coma, prior to intubation for respiratory insuffi ciency (pg 56). Grade C, Level 2+ D In bradycardia due to calcium channel or beta-blocker toxicity that is refractory to conventional vasopressor therapy, intravenous calcium, glucagon or insulin should be used (pg 57). Grade D, Level 3 B Patients with actual or potential life threatening cardiac arrhythmia, hyperkalaemia or rapidly progressive toxicity from digoxin poisoning should be treated with digoxin-specifi c antibodies (pg 57). Grade B, Level 2++ B Titrated doses of benzodiazepine should be given in hyperadrenergic- induced tachycardia states resulting from poisoning (pg 57). Grade B, Level 1+ D Non-selective beta-blockers, like propranolol, should be avoided in stimulant toxicity as unopposed alpha agonism may worsen accompanying hypertension (pg 57). -
Pharmacology/Therapeutics Ii Block 1 Handouts – 2015-16
PHARMACOLOGY/THERAPEUTICS II BLOCK 1 HANDOUTS – 2015‐16 55. H2 Blockers, PPls – Moorman 56. Palliation of Contipation & Nausea/Vomiting – Kristopaitis 57. On‐Line Only – Principles of Clinical Toxicology – Kennedy 58. Anti‐Parasitic Agents – Johnson Histamine Antagonists and PPIs January 6, 2016 Debra Hoppensteadt Moorman, Ph.D. Histamine Antagonists and PPIs Debra Hoppensteadt Moorman, Ph.D. Office # 64625 Email: [email protected] KEY CONCEPTS AND LEARNING OBJECTIVES . 1 To understand the clinical uses of H2 receptor antagonists. 2 To describe the drug interactions associated with the use of H2 receptor antagonists. 3 To understand the mechanism of action of PPIs 4 To describe the adverse effects and drugs interactions with PPIs 5 To understand when the histamine antagonists and the PPIs are to be used for treatment 6 To describe the drugs used to treat H. pylori infection Drug List: See Summary Table. Histamine Antagonists and PPIs January 6, 2016 Debra Hoppensteadt Moorman, Ph.D. Histamine Antagonists and PPIs I. H2 Receptor Antagonists These drugs reduce gastric acid secretion, and are used to treat peptic ulcer disease and gastric acid hypersecretion. These are remarkably safe drugs, and are now available over the counter. The H2 antagonists are available OTC: 1. Cimetidine (Tagamet®) 2. Famotidine (Pepcid®) 3. Nizatidine (Axid®) 4. Ranitidine (Zantac®) All of these have different structures and, therefore, different side-effects. The H2 antagonists are rapidly and well absorbed after oral administration (bioavailability 50-90%). Peak plasma concentrations are reached in 1-3 hours, and the drugs have a t1/2 of 1-3 hours. H2 antagonists also inhibit stimulated (due to feeding, gastrin, hypoglycemia, vagal) acid secretion and are useful in controlling nocturnal acidity – useful when added to proton pump therapy to control “nocturnal acid breakthrough”. -
Cyanide Poisoning and How to Treat It Using CYANOKIT (Hydroxocobalamin for Injection) 5G
Cyanide Poisoning and How to Treat It Using CYANOKIT (hydroxocobalamin for injection) 5g 1. CYANOKIT (single 5-g vial) [package insert]. Columbia, MD: Meridian Medical Technologies, Inc.; 2011. Please see Important Safety Information on slides 3-4 and full Prescribing Information for CYANOKIT starting on slide 33. CYANOKIT is a registered trademark of SERB Sarl, licensed by Meridian Medical Technologies, Inc., a Pfizer company. Copyright © 2015 Meridian Medical Technologies, Inc., a Pfizer company. All rights reserved. CYK783109-01 November/2015. Indication and Important Safety Information……………………………………………………………………………….………..…..3 . Identifying Cyanide Poisoning……………………………………………………………………………………………………………….…………….….5 . How CYANOKIT (hydroxocobalamin for injection) Works……………………………………………………………….12 . The Specifics of CYANOKIT…………………………………………………………………………………………………………………………….………17 . Administering CYANOKIT………………………………………………………………………………………………………………………………..……….21 . Storage and Disposal of CYANOKIT…................................................................................................................................26 . Grant Information for CYANOKIT……………………………………………………………………………………………………………………....30 . Full Prescribing Information………………………………………………………………………………………………….………………………………33 Please see Important Safety Information on slides 3-4 and full Prescribing Information for CYANOKIT starting on slide 33. CYANOKIT (hydroxocobalamin for injection) 5 g for intravenous infusion is indicated for the treatment of known or suspected cyanide poisoning. -
Poisoning in Children
ARTICLE IN PRESS Current Paediatrics (2005) 15, 563–568 www.elsevier.com/locate/cupe Poisoning in children Fiona JepsenÃ, Mary Ryan Emergency Medicine, Royal Liverpool Children’s NHS Trust, Alder Hey, Liverpool L12 2AP, UK KEYWORDS Summary Poisoning accounts for about 7% of all accidents in children under 5 Poisoning; years and is implicated in about 2% of all childhood deaths in the developed world, Child; and over 5% in the developing world (National Poisons Information Service). In Accidents; considering this topic, however, it is important to differentiate accidental overdose Home (common in the younger age groups) and deliberate overdose (more common in young adults). Although initial assessment and treatment of these groups may not differ significantly, the social issues and ongoing follow-up of these children will be totally different and the treating physician must remain aware of this difference. The initial identification and treatment of these children remains the mainstay of management, and many ingested substances do not have a specific antidote. Supportive treatment must be planned and the potential for delayed or long-term effects noted. The specific presentation and treatment of some of the commonly ingested substances will be addressed in this article, and guidance given on when to contact expert help. & 2005 Elsevier Ltd. All rights reserved. Introduction such as bleaches, detergents and turpentine sub- stitutes. More than 100 000 individuals are admitted to Toxic compounds may be ingested or inhaled hospital in England and Wales annually due to either accidentally or deliberately. Accidental poisoning, accounting for 10% of all acute admis- poisoning can occur at any age, but is much more 1 sions.1 However, the true incidence of acute common in children. -
Acute Poisoning: Understanding 90% of Cases in a Nutshell S L Greene, P I Dargan, a L Jones
204 REVIEW Postgrad Med J: first published as 10.1136/pgmj.2004.027813 on 5 April 2005. Downloaded from Acute poisoning: understanding 90% of cases in a nutshell S L Greene, P I Dargan, A L Jones ............................................................................................................................... Postgrad Med J 2005;81:204–216. doi: 10.1136/pgmj.2004.024794 The acutely poisoned patient remains a common problem Paracetamol remains the most common drug taken in overdose in the UK (50% of intentional facing doctors working in acute medicine in the United self poisoning presentations).19 Non-steroidal Kingdom and worldwide. This review examines the initial anti-inflammatory drugs (NSAIDs), benzodiaze- management of the acutely poisoned patient. Aspects of pines/zopiclone, aspirin, compound analgesics, drugs of misuse including opioids, tricyclic general management are reviewed including immediate antidepressants (TCAs), and selective serotonin interventions, investigations, gastrointestinal reuptake inhibitors (SSRIs) comprise most of the decontamination techniques, use of antidotes, methods to remaining 50% (box 1). Reductions in the price of drugs of misuse have led to increased cocaine, increase poison elimination, and psychological MDMA (ecstasy), and c-hydroxybutyrate (GHB) assessment. More common and serious poisonings caused toxicity related ED attendances.10 Clinicians by paracetamol, salicylates, opioids, tricyclic should also be aware that severe toxicity can result from exposure to non-licensed pharmaco- -
Hospital Formulary (List of Drugs, Chemicals & Dressing Material)
Hospital Formulary (List of drugs, chemicals & dressing material) Department of Pharmacy Government Medical College Hospital Sector-32, Chandigarh Compiled by: Jayati Khurana (M.Pharmacy in Pharmaceutics) Department of Pharmacy - In The Service of Humanity Prof Ravi Gupta Head Pharmacy Ms. Neetu Verma Dispensary Superintendent Ms. Manjeet Kaur Pharmacist Ms. Kuldeep Kaur Pharmacist Ms. Neelam Pharmacist Ms. Parveen Lata Pharmacist Ms. Monika Verma Pharmacist Mr. Jatinder Singh Pharmacist Ms. Bharti Rawat Pharmacist Ms. Neetu Verma Pharmacist Mr. Satinder Parkash Pharmacist Mr. Ravinder Pharmacist Ms. Rachna Bisht Pharmacist Ms. Alka Sinhmar Pharmacist Ms. Nisha Rani Pharmacist Ms. Pooja Pharmacist Ms. Charu Pharmacist Ms. Jayati Khurana Pharmacist Ms. Monika Yadav Pharmacist Ms. Kala Wanti Senior Assistant Ms. Vandana Junior Assistant Mr. Chhinder Data Entry Operator INDEX S. No. Pharmacological Category Page number 1 Abortifacients/Uterine stimulants 1 2 Alkalizing agent 1 3 Alpha-1 Blocker 1 4 Aminoglycoside antibiotics (Bactericidal) 1 5 Analgesic-Anti-inflammatory drugs 2-3 6 Antacids 3 7 Anti-acne drugs 4 8 Anti-allergic drugs 4 9 Anti-amoebic drugs 4 10 Antianginal drugs 4-5 11 Anti-anxiety drugs 5 12 Antiarrhythmic drugs 6 13 Antiarrhythmics-Local Anesthetics 6 14 Antiasthmatic drugs 6-8 15 Anticancer drugs 8-10 16 Anticholinergic drugs 10 17 Anti-coagulant 10-11 18 Antidepressants 11 19 Antidiarrhoeal drugs 12 20 Anti-Diuretic Hormone 12 21 Antidotes 12-13 22 Anti-Emetic drugs 13-14 23 Anti-Epileptics 14-15 24 Antifungal drugs 15-16 25 Anthelminthic drugs 16 26 Antihistamines 17 27 Anti-hyperglycemics 17 28 Antihypertensive drugs 18 29 Antiinflammatory-local anesthetics 18 30 Anti-leishmaniasis (Kala-azar) 18 31 Anti-leprotics 19 32 Anti-malarial drugs 19-20 33 Antimaniac drugs 20 34 Antiparkison drugs 21 35 Anti-peptic ulcers 21-22 36 Antiplatelets 22 37 Anti-psoriatics 22 38 Anti-psychotics 22-23 39 Anti-pyretics 23 40 Anti-scabies/Anti-lice 23 41 Antiseptic-Disinfectants 23-24 42 Antispasmodics 24-25 43 Anti-T.B. -
Cassava Cyanide Diseases & Neurolathyrism Network Issue Number 20, December 2012
Working together to eliminate cyanide poisoning, konzo, tropical ataxic neuropathy (TAN) and neurolathyrism Cassava Cyanide Diseases & Neurolathyrism Network (ISSN 1838-8817 (Print): ISSN 1838-8825 (Online) Issue Number 20, December 2012 Contents Historical Awareness of Neurolathyrism, Historical Awareness of Neurolathyrism, and Cassava Toxicity and Cassava Toxicity ................................... 1 Most people studying lathyrism are likely to Acute cyanide poisoning from cassava: is have training in bio-scientific methods or in social it still common? ........................................... 4 science, yet there are considerable gaps of thinking International conference on “Recent and practice between different disciplines, e.g. from plant biologists to historians of food in human Trends in Lathyrus sativus Research” cultures. There are different approaches to what is (Hyderabad, India, November 8-9, 2012). ... 6 considered ‘well-founded knowledge’, and how it Neurolathyrism in Bidar and Medak may be established. This paper recognises such districts of South India ................................ 7 differences, and their relevance to knowledge- Residual Cyanide content In Cassava development in neurolathyrism, with brief Product of India ............................................ 7 comparison of cassava (manioc) and its toxicity. It also considers why a broader approach to knowledge is important, and whether historical CCDNN Coordinators: knowledge can be made useful to people who face Prof Fernand Lambein increased food scarcity, and are ‘below the radar’ of Ghent University, Institute for plant Biotechnology government attention. Outreach (IPBO) Review articles in lathyrism often begin with a Proeftuinstraat 86 N1, B-9000 Ghent, Belgium Phone: +32 484 417 5005 glimpse of history, citing ancient texts where E-mail: [email protected] or Lathyrus sativus seems to appear, or [email protected] archaeological reports of seeds found from antiquity. -
Critical Care Nursing of Infants and Children Martha A
University of Pennsylvania ScholarlyCommons Miscellaneous Papers Miscellaneous Papers 1-1-2001 Critical Care Nursing of Infants and Children Martha A. Q. Curley University of Pennsylvania, [email protected] Patricia A. Moloney-Harmon The Children's Hospital at Sinai Copyright by the author. Reprinted from Critical Care Nursing of Infants and Children, Martha A.Q. Curley and Patricia A. Moloney-Harmon (Editors), (Philadelphia: W.B. Saunders Co., 2001), 1,128 pages. NOTE: At the time of publication, the author, Martha Curley was affiliated with the Children's Hospital of Boston. Currently, she is a faculty member in the School of Nursing at the University of Pennsylvania. This paper is posted at ScholarlyCommons. http://repository.upenn.edu/miscellaneous_papers/4 For more information, please contact [email protected]. Please Note: The full version of this book and all of its chapters (below) can be found on ScholarlyCommons (from the University of Pennsylvania) at http://repository.upenn.edu/miscellaneous_papers/4/ Information page in ScholarlyCommons Full book front.pdf - Front Matter, Contributors, Forward, Preface, Acknowledgements, and Contents Chapter 1.pdf - The Essence of Pediatric Critical Care Nursing Chapter 2.pdf - Caring Practices: Providing Developmentally Supportive Care Chapter_3.pdf - Caring Practices: The Impact of the Critical Care Experience on the Family Chapter_4.pdf - Leadership in Pediatric Critical Care Chapter 5.pdf - Facilitation of Learning Chapter_6.pdf - Advocacy and Moral Agency: A Road Map for -
Chelation Therapy
Corporate Medical Policy Chelation Therapy File Name: chelation_therapy Origination: 12/1995 Last CAP Review: 2/2021 Next CAP Review: 2/2022 Last Review: 2/2021 Description of Procedure or Service Chelation therapy is an established treatment for the removal of metal toxins by converting them to a chemically inert form that can be excreted in the urine. Chelation therapy comprises intravenous or oral administration of chelating agents that remove metal ions such as lead, aluminum, mercury, arsenic, zinc, iron, copper, and calcium from the body. Specific chelating agents are used for particular heavy metal toxicities. For example, desferroxamine (not Food and Drug Administration [FDA] approved) is used for patients with iron toxicity, and calcium-ethylenediaminetetraacetic acid (EDTA) is used for patients with lead poisoning. Note that disodium-EDTA is not recommended for acute lead poisoning due to the increased risk of death from hypocalcemia. Another class of chelating agents, called metal protein attenuating compounds (MPACs), is under investigation for the treatment of Alzheimer’s disease, which is associated with the disequilibrium of cerebral metals. Unlike traditional systemic chelators that bind and remove metals from tissues systemically, MPACs have subtle effects on metal homeostasis and abnormal metal interactions. In animal models of Alzheimer’s disease, they promote the solubilization and clearance of β-amyloid protein by binding to its metal-ion complex and also inhibit redox reactions that generate neurotoxic free radicals. MPACs therefore interrupt two putative pathogenic processes of Alzheimer’s disease. However, no MPACs have received FDA approval for treating Alzheimer’s disease. Chelation therapy has also been investigated as a treatment for other indications including atherosclerosis and autism spectrum disorder. -
Pattern of Paracetamol Poisoning: Influence on Outcome and Complications
toxics Article Pattern of Paracetamol Poisoning: Influence on Outcome and Complications Diego Castanares-Zapatero 1, Valérie Dinant 1, Ilaria Ruggiano 1, Harold Willem 1, Pierre-François Laterre 1 and Philippe Hantson 1,2,* 1 Department of Intensive Care, Cliniques St-Luc, Université catholique de Louvain, 1200 Brussels, Belgium; [email protected] (D.C.-Z.); [email protected] (V.D.); [email protected] (I.R.); [email protected] (H.W.); [email protected] (P.-F.L.) 2 Louvain Centre for Toxicology and Applied Pharmacology, 1200 Brussels, Belgium * Correspondence: [email protected]; Tel.: +00-327-642-755 Received: 5 September 2018; Accepted: 28 September 2018; Published: 29 September 2018 Abstract: Acute paracetamol poisoning due to a single overdose may be effectively treated by the early administration of N-acetylcysteine (NAC) as an antidote. The prognosis may be different in the case of intoxication due to multiple ingestions or when the antidote is started with delay. The aim of this work was to investigate the outcome of paracetamol poisoning according to the pattern of ingestion and determine the factors associated with the outcome. We performed a retrospective analysis over the period 2007–2017 of the patients who were referred to a tertiary hospital for paracetamol-related hepatotoxicity. Inclusion criteria were: accidental or voluntary ingestion of paracetamol, delay for NAC therapy of 12 h or more, liver enzymes (ALT) >1000 IU/L on admission. Ninety patients were considered. Poisoned patients following multiple ingestion were significantly older (45 ± 12 vs. 33 ± 14) (p = 0.001), with a higher incidence of liver steatosis (p = 0.016) or chronic ethanol abuse (p = 0.04). -
Question of the Day Archives: Monday, December 5, 2016 Question: Calcium Oxalate Is a Widespread Toxin Found in Many Species of Plants
Question Of the Day Archives: Monday, December 5, 2016 Question: Calcium oxalate is a widespread toxin found in many species of plants. What is the needle shaped crystal containing calcium oxalate called and what is the compilation of these structures known as? Answer: The needle shaped plant-based crystals containing calcium oxalate are known as raphides. A compilation of raphides forms the structure known as an idioblast. (Lim CS et al. Atlas of select poisonous plants and mushrooms. 2016 Disease-a-Month 62(3):37-66) Friday, December 2, 2016 Question: Which oral chelating agent has been reported to cause transient increases in plasma ALT activity in some patients as well as rare instances of mucocutaneous skin reactions? Answer: Orally administered dimercaptosuccinic acid (DMSA) has been reported to cause transient increases in ALT activity as well as rare instances of mucocutaneous skin reactions. (Bradberry S et al. Use of oral dimercaptosuccinic acid (succimer) in adult patients with inorganic lead poisoning. 2009 Q J Med 102:721-732) Thursday, December 1, 2016 Question: What is Clioquinol and why was it withdrawn from the market during the 1970s? Answer: According to the cited reference, “Between the 1950s and 1970s Clioquinol was used to treat and prevent intestinal parasitic disease [intestinal amebiasis].” “In the early 1970s Clioquinol was withdrawn from the market as an oral agent due to an association with sub-acute myelo-optic neuropathy (SMON) in Japanese patients. SMON is a syndrome that involves sensory and motor disturbances in the lower limbs as well as visual changes that are due to symmetrical demyelination of the lateral and posterior funiculi of the spinal cord, optic nerve, and peripheral nerves. -
Publications for Nicholas Buckley 2021 2020
Publications for Nicholas Buckley 2021 href="http://dx.doi.org/10.1002/prp2.695">[More Brett, J., Pearson, S., Daniels, B., Wylie, C., Buckley, N. Information]</a> (2021). A cross sectional study of psychotropic medicine use in Crouse, J., Morley, K., Buckley, N., Dawson, A., Seth, D., Australia in 2018: A focus on polypharmacy. British Journal of Monds, L., Tickell (nee Kennedy), A., Kay-Lambkin, F., Clinical Pharmacology, 87(3), 1369-1377. <a Chitty, K. (2021). Online interventions for people hospitalized href="http://dx.doi.org/10.1111/bcp.14527">[More for deliberate self-harm and problematic alcohol use: Lessons Information]</a> learned from the iiAIM trial. Bulletin of the Menninger Clinic, Chiew, A., Buckley, N. (2021). Acetaminophen Poisoning. 85(2), 123-142. <a Critical Care Clinics, 37(3), 543-561. <a href="http://dx.doi.org/10.1521/bumc.2021.85.2.123">[More href="http://dx.doi.org/10.1016/j.ccc.2021.03.005">[More Information]</a> Information]</a> Perananthan, V., Buckley, N. (2021). Opioids and Hurzeler, T., Buckley, N., Noghrehchi, F., Malouf, P., Page, A., antidepressants: Which combinations to avoid. Australian Schumann, J., Chitty, K. (2021). Alcohol-related suicide across Prescriber, 44(2), 41-44. <a Australia: a geospatial analysis. Australian and New Zealand href="http://dx.doi.org/10.18773/austprescr.2021.004">[More Journal of Public Health, 45(4), 394-399. <a Information]</a> href="http://dx.doi.org/10.1111/1753-6405.13122">[More Ly, J., Brown, J., Buckley, N., Cairns, R. (2021). Paediatric Information]</a> poisoning exposures in schools: Reports to Australia's largest Huang, J., Buckley, N., Isoardi, K., Chiew, A., Isbister, G., poisons centre.